TORONTO, Ontario, July 14, 2026
Cardiol Therapeutics Inc. has announced the publication of its Phase II MAvERIC clinical trial results evaluating CardiolRx™ in patients with recurrent pericarditis in the Journal of the American Heart Association (JAHA). The peer-reviewed publication represents a significant milestone for the company’s cardiovascular drug development program and further strengthens the scientific foundation supporting its ongoing pivotal Phase III MAVERIC trial, which is now approaching full patient enrollment. The published findings demonstrated that CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation, alongside meaningful decreases in disease recurrence and a favorable safety and tolerability profile. These encouraging results provide additional evidence supporting the investigational therapy’s potential to become a non-immunosuppressive treatment for patients suffering from recurrent pericarditis, a chronic inflammatory heart condition that frequently causes debilitating chest pain, shortness of breath, repeated hospitalizations, and reduced quality of life. The publication also reinforces Cardiol Therapeutics’ growing position in the development of anti-inflammatory and anti-fibrotic cardiovascular therapies addressing significant unmet medical needs.
Phase II Results Strengthen Pivotal Phase III MAVERIC Trial
The MAvERIC Phase II study demonstrated clinically meaningful improvements across several important efficacy endpoints, including significant reductions in pericarditis pain, inflammatory activity, and the annual frequency of disease recurrences among patients with a high baseline disease burden. Importantly, CardiolRx™ also demonstrated a favorable safety and tolerability profile, supporting continued evaluation in larger randomized clinical studies. These findings directly informed the design of the ongoing Phase III MAVERIC trial, a randomized, double-blind, placebo-controlled study evaluating whether CardiolRx™ can reduce the risk of recurrent pericarditis episodes. With patient enrollment now nearing completion, the pivotal study is expected to generate the robust clinical evidence required to support future regulatory submissions. Company leadership noted that the strong investigator and patient interest in the trial reflects the continued need for innovative therapies capable of improving long-term outcomes without relying on chronic immunosuppressive treatment strategies.
CardiolRx™ Targets Inflammation in Cardiovascular Disease
CardiolRx™ is Cardiol Therapeutics’ lead small-molecule drug candidate, specifically designed to modulate inflammasome pathway activation, a key component of the innate immune response implicated in inflammation and fibrosis affecting cardiovascular tissues. By targeting this underlying inflammatory mechanism, the therapy is being developed for several serious heart conditions, including recurrent pericarditis, acute myocarditis, and potentially heart failure. The investigational therapy has already received U.S. FDA Orphan Drug Designation for the treatment of pericarditis, recognizing both the rarity of the condition and the need for improved therapeutic options. In addition to the ongoing MAVERIC Program, Cardiol Therapeutics has completed its ARCHER Phase II study evaluating CardiolRx™ in acute myocarditis and continues advancing CRD-38, a novel subcutaneous formulation intended for inflammatory heart disease. Together, these programs reflect the company’s broader strategy of developing innovative therapies that address inflammation-driven cardiovascular disorders.
Advertisement
Peer-Reviewed Publication Reinforces Clinical Development Strategy
Publication in the Journal of the American Heart Association, one of the world’s leading peer-reviewed cardiovascular journals, provides important independent scientific validation of the Phase II findings while increasing visibility among cardiologists, clinical researchers, and regulatory stakeholders. As the Phase III MAVERIC trial approaches enrollment completion, the newly published data provide additional confidence in the clinical rationale supporting CardiolRx™ and its potential to advance the standard of care for recurrent pericarditis. If future pivotal results confirm the positive outcomes observed in Phase II, Cardiol Therapeutics could offer physicians a differentiated treatment option capable of reducing inflammation and disease recurrence while avoiding the long-term risks associated with immunosuppressive therapies. The publication therefore represents another important milestone in the company’s effort to deliver innovative therapies for patients living with inflammatory cardiovascular diseases that currently have limited treatment options.
Source: Cardiol Therapeutics press release
